Twelve-month Outcomes of Dexamethasone Implant Treatment in Macular Edema Secondary to Retinal Vein Occlusion in Real Life

Özkaya, Abdullah

doi:10.14744/bej.2017.36844

Cited by 3 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…e risk for cataract is higher after two injections of dexamethasone intravitreal implant [21]. Ozkaya et al [8] reported a rate of cataract of 4.4% after a single intravitreal dexamethasone injection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up

Nicula

Nicula²,

Rednik³

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. The purpose of the study was to assess the efficacy of intravitreal dexamethasone implant (IDI: Ozurdex®) injection in eyes with macular edema due to retinal vein occlusion. Material and Method. A retrospective, nonrandomized study was conducted in patients with macular edema (ME) due to retinal vein occlusion (RVO) who undertook intravitreal Ozurdex® as first-line treatment. We performed a complete ocular exam including macular OCT. Results. The mean BCVA (logMar) improved from 0.420.42 ± 0.23 logMar at baseline to 0.21 ± 0.23 logMar at 48 weeks in the BRVO group and from 0.72 ± 0.16 logMar at baseline to 0.31 ± 0.23 logMar at 48 weeks in the CRVO group. In both groups, CFT values decreased significantly compared to baseline (p<0.0001 at each timepoint). Reinjection for recurrent macular edema after 18 weeks was indicated in five eyes (41.67%) in the BRVO group and in six eyes (25%) in the CRVO group. Cataract developed in two eyes (16.67%) in the BRVO group and in one eye (4.17%) in the CRVO group. The IOP was higher than 25 mmHg in two cases in the BRVO group (16.66%) and in three cases (8.33%) in the CRVO group. Conclusion. Ozurdex® injected intravitreally significantly improved the mean CFT and BCVA in eyes with macular edema due to retinal vein occlusion.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It was approved for use in the treatment of RVO in the United States of America (USA), Europe, and Switzerland. Several studies showed that intravitreal steroid injections have anti-inflammatory, antiangiogenic, and antivascular permeability characteristics and are effective for treating RVO-related ME [1,2,[6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up

Nicula

Nicula²,

Rednik³

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…reported a cataract surgery rate of 4.4% after a single IDI injection. [ 35 ] In a wide-series study by Eter et al . involving 573 patients, the cataract surgery rate was 6.1% after a mean of 1.17 IDI injections.…”

Section: Discussionmentioning

confidence: 99%

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario

Şimşek

Çıtırık

Özateş

et al. 2018

Indian J Ophthalmol

View full text Add to dashboard Cite

Purpose:This study evaluated the effect of intravitreal dexamethasone implant (IDI; Ozurdex) injection for treating macular edema in patients with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).Methods:This prospective study included 40 eyes of 40 patients with nonischemic BRVO and 31 eyes of 31 patients with nonischemic CRVO who received IDI injection as the first-line treatment for macular edema. The best-corrected visual acuity (BCVA) value before and after the treatment; intraocular pressure; optic coherence tomography findings; and all ocular examination findings, including central foveal thickness (CFT) measurement and fluorescein angiography findings, were evaluated for each patient.Results:After the IDI injection, BCVA value increased (P < 0.001) and CFT value decreased (P < 0.001) in both groups. The recurrence rates of CFT elevation after the first and the second Ozurdex injections were 65.0% and 65.3%, respectively, in patients with BRVO and 70.9% and 68.1%, respectively, in patients with CRVO. A statistically significant correlation was observed between preinjection CFT value and postinjection recurrence of CFT elevation (P = 0.017).Conclusion:Treatment with the IDI injections resulted in significant short-term improvement in CFT and BCVA values in patients with clinically significant RVO-related macular edema. Moreover, we observed that high preinjection CFT value was associated with a risk of postinjection recurrence of CFT elevation.

show abstract

“…However, intravitreal triamcinolone treatment is associated with severe ocular side effects, including cataract and elevated intraocular pressure (IOP). Previous studies suggest that a biodegradable intravitreal dexamethasone implant (IDI) (Ozurdex, 0.7 mg; Allergan Inc., Irvine, CA, USA) improves visual acuity and macular thickness in patients showing agerelated macular degeneration (6), retinal vein occlusion (7), and diabetic retinopathy-related macular edema (8). The IDI injection is associated with a better safety profile and results in better improvements in visual acuity and macular edema than the intravitreal triamcinolone injection.…”

Section: Introductionmentioning

confidence: 99%

The Efficacy of Single Dose Intravitreal Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-VEGF Therapy: A Real-Life Results

Şimşek¹

2020

Beyoglu Eye J

View full text Add to dashboard Cite

To investigate the efficacy, safety, and side effect profiles of a single-dose intravitreal dexamethasone implant (IDI, Ozurdex) in patients with diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (VEGF) therapy. Methods: This study included 101 eyes of 78 diabetic patients with DME that remained persistent despite administering at least six doses of anti-VEGF therapy. The patients were evaluated at baseline and were followed up monthly until the sixth month after the IDI injection. The primary outcomes were central foveal thickness (CFT) and best-corrected visual acuity (BCVA). Results: The mean number of anti-VEGF injection administered to patients was 6.50±0.33. One month after the last injection, the response to treatment was evaluated. IDI injection was performed approximately 1.14±0.08 months after the last anti-VEGF injection. After the IDI injection, BCVA value increased (p<0.001) and CFT value decreased (p<0.001). The peak effect of the IDI was observed in the second month after the injection. CFT values increased and BCVA values decreased from the beginning of the fourth month after the IDI injection. The recurrence rate of CFT elevation in the sixth-month follow-up was 57.4%. Moreover, we observed that high pre-injection CFT values were correlated with a high post-injection recurrence rate of CFT elevation (p<0.001). Conclusion: These findings suggest that the IDI injection significantly improves BCVA and CFT values in patients with DME refractory to anti-VEGF therapy. However, recurrence of CFT elevation may occur in >50% patients in the sixth month after the first injection.

show abstract

Twelve-month Outcomes of Dexamethasone Implant Treatment in Macular Edema Secondary to Retinal Vein Occlusion in Real Life

Cited by 3 publications

References 6 publications

Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up

Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario

The Efficacy of Single Dose Intravitreal Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-VEGF Therapy: A Real-Life Results

Contact Info

Product

Resources

About